Did You Know...
...that it was melting ice cream that inspired the invention of the outboard motor? It was a lovely August day and Ole Evinrude was rowing his boat to his favorite island picnic spot. As he rowed, he watched his ice cream melt and wished he had a faster way to get to the island. At that moment the idea for the outboard motor was born!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8119138 | Anti-estrogen and immune modulator combinations for treating breast cancer Compositions for treating cancers of mucosal tissues including breast, prostate, ovary, colon are disclosed which include various combinations of new or conventional anti-estrogen compounds, aromatase inhibitors, immune modulators, immune inhibitors, immune inhibito... | 02/21/2012 |
| 8114403 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-de... | 02/14/2012 |
| 8110194 | CTLA-4 antibody dosage escalation regimens A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reac... | 02/07/2012 |
| 8038999 | Breast cancer eradication program A method of treating breast cancer that is at least partially ER+ is disclosed. The method comprises administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of Fe(II) or Fe(III) in a suitable carrier. A four-part program ai... | 10/18/2011 |
| 8025883 | Antagonists and methods for inhibiting angiogenesis The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for... | 09/27/2011 |
| 8003105 | Method of treating cancer by co-administration of anticancer agents The present invention relates to a method of treating cancer by co-administration of an effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and an effective amount of one or more antica... | 08/23/2011 |
| 7972600 | IGF-IR antagonists as adjuvants for treatment of prostate cancer The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, survi... | 07/05/2011 |
| 7959923 | Method for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding... | 06/14/2011 |
| 7947275 | Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth Serum-containing and serum-free immunoglobulin inhibitors of steroid hormone responsive cancer cell growth are disclosed, along with their methods of production. Also disclosed are defined cell culture media, assay protocols, and model systems using the inhibitors f... | 05/24/2011 |
| 7910108 | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases The present invention is directed to pharmaceutical methods for the treatment of CD30 positive diseases, such as Hodgkin's disease, by administration of a combination of at least one sheddase inhibitor and at least one anti-CD30 immunotherapeutic. ... | 03/22/2011 |
| 7887808 | Human Rgr oncogene and truncated transcripts thereof detected in T cell malignancies, antibodies to the encoded polypeptides and methods of use Naturally-occurring variants of human Rgr oncogene protein, in particular, abnormally truncated variants found in T cell malignancies, as well as the human Rgr protein are encompassed by the present invention. Also included are antibodies thereto and nucleic acid mo... | 02/15/2011 |
| 7837998 | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody Monoclonal antibodies to thymidine kinase 1 are disclosed which are useful in methods of detecting, diagnosing, and treating cancer. ... | 11/23/2010 |
| 7749504 | Anti-TAT188 antibodies The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. ... | 07/06/2010 |
| 7744889 | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders αβ-Unsaturated sulfoxides of Formula I: are useful as antiproliferative agents including, for example, anticancer agents, and as radioprotective and chemoprotective agents. | 06/29/2010 |
| 7727530 | Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody The present invention relates to a pharmaceutical composition comprising of proline or proline derivatives or their salts, esters, isomers, racemates, enantiomeres or prodrugs together with an anti-cancer ligand, preferably an antibody directed to a tumour antigen. ... | 06/01/2010 |
| 7691380 | Combined methods for tumor coagulation and tumor treatment Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecif... | 04/06/2010 |
| 7674462 | Cripto blocking antibodies and uses thereof The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4... | 03/09/2010 |
| 7662383 | Chimeric antibody against tumor associated antigens and its use in diagnosing tumors The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put t... | 02/16/2010 |
| 7658924 | Angiopoietin-2 specific binding agents Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies. ... | 02/09/2010 |
| 7622118 | Cancer treatment methods using selected antibodies to aminophospholipids Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Al... | 11/24/2009 |
| 7615221 | Compositions and methods for treating cancer The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types. ... | 11/10/2009 |
| 7582299 | Cripto-specific antibodies The invention provides Cripto-specific antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and inhibit Cripto activity are provided. Antibodies which bind Cripto and inhibit the interaction between Cripto and ALK4... | 09/01/2009 |
| 7572448 | Combined cancer treatment methods using selected antibodies to aminophospholipids Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Al... | 08/11/2009 |
| 7563444 | Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides... | 07/21/2009 |
| 7544358 | Treatment of acute lung injury, fibrosis and metastasis with antagonists of αvβ6 Methods and compositions comprising antagonists of αvβ6 are provided for the treatment of acute lung injury fibrosis. ... | 06/09/2009 |
| 7521053 | Angiopoietin-2 specific binding agents Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies. ... | 04/21/2009 |
| 7435412 | Chronic lymphocytic leukemia cell line The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are usefu... | 10/14/2008 |
| 7435803 | Anti-CD20 antibodies and fusion proteins thereof and methods of use The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignan... | 10/14/2008 |
| 7432359 | Anti-A33 antibody The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or t... | 10/07/2008 |
| 7429381 | Production and use of novel peptide-based agents for use with bi-specific antibodies The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antib... | 09/30/2008 |
| 7423127 | Antibodies to a polypeptide encoded by a nucleic acid overexpressed in melanoma The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 09/09/2008 |
| 7422739 | Anti-CD20 antibodies Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. ... | 09/09/2008 |
| 7419667 | Drug for cancer therapy A lactoferrin hydrolysate mixture or lactoferrin partial peptide that can be obtained by hydrolyzing lactoferrin with a hydrolytic enzyme and has an action of enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer is used as an active ingr... | 09/02/2008 |
| 7416726 | Enhancement of antibody-mediated immune responses The present invention is related to enhancing the function of anti-tumor antibodies by regulating FcγRIIB-mediated activity. In particular, disrupting SHIP activation by FcγRIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The inven... | 08/26/2008 |
| 7413737 | Anti-hydroxylase antibodies and uses thereof Antibodies, or antigen-binding portions thereof, to aspartyl (asparaginyl) β-hydroxylase are provided. The anti-aspartyl (asparaginyl) β-hydroxylase antibodies, or antigen-binding portions thereof, can modulate activity of aspartyl (asparaginyl) β-hydroxylase. | 08/19/2008 |
| 7414073 | Cytotoxic agents containing novel potent taxanes and their therapeutic use Included within the scope of the present invention are potent taxanes and taxanes containing a linking group. Also included is a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for inducing cell death in selec... | 08/19/2008 |
| 7413736 | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The h... | 08/19/2008 |
| 7411046 | Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ... | 08/12/2008 |
| 7407656 | PSCA: prostate stem cell antigen and uses thereof The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and an... | 08/05/2008 |
| 7402385 | Radiolabeled antibodies for treatment of tumors This invention provides methods for imaging and/or treating a tumor in a subject which comprise administering to the subject an amount of a radiolabeled antibody effective to image and/or treat the tumor, where the radiolabeled antibody binds to a cellular component... | 07/22/2008 |
